Prognosis
Glaxo’s Covid Vaccine Partnership With Clover Begins Human Tests
This article is for subscribers only.
GlaxoSmithKline Plc’s Covid-19 vaccine partnership with Clover Biopharmaceuticals started tests in humans, following a number of other programs in the sprint to come up with a weapon to try to halt the pandemic.
Initial results from the study are expected in August, and a bigger efficacy trial is expected to start later in 2020, Glaxo said in a statement Friday.